Trends in Human Papillomavirus–Associated Cancers — United States, 1999–2015

Elizabeth A. Van Dyne(Centers for Disease Control and Prevention), Vicki B. Benard(Centers for Disease Control and Prevention), Lauri E. Markowitz(Centers for Disease Control and Prevention), S. Jane Henley(Centers for Disease Control and Prevention), Mona Saraiya(Merck & Co., Inc., Rahway, NJ, USA (United States)), Cheryll C. Thomas(Office of Science)
MMWR Morbidity and Mortality Weekly Report
August 23, 2018
10.15585/mmwr.mm6733a2
Cited by 516

Related Papers

Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP)
|PsycEXTRA Dataset|2007|1.9k
Prevalence of HPV Infection Among Females in the United States
|JAMA|2007|1.6k
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis
|The Lancet|2019|1.3k
Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices.
|PubMed|2015|1.1k
Trends in Herpes Simplex Virus Type 1 and Type 2 Seroprevalence in the United States
|JAMA|2006|1k